Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)
20240124
Phase 1 other active
Quick answer
Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310) for Extensive Stage Small Cell Lung Cancer (ES-SCLC) is a Phase 1 program (other) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Phase
- Phase 1
- Modality
- other
- Status
- active